Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

Alchemab Therapeutics enters $415 million licensing agreement with Eli Lilly for ATLX-1282: Cambridge, UK Wednesday, May 7, 2025, 12:00 Hrs [IST] Alchemab Therapeutics (Alchemab), ...

近年来，礼来在生物医药领域动作频频，展现出强大的布局野心。今年 1 月，礼来签订了多项合作协议，其中包括以 7.8 亿美元的授权协议获得 Mediar Therapeutics 公司的特发性肺纤维化药物，以及与 Scorpion ...

在生物医药领域，研发投入与合作布局是企业发展的关键驱动力。礼来近年来在这一领域的频繁动作，彰显了其强大的市场野心。除了渐冻症，礼来还与多家公司合作，涉及特发性肺纤维化、心血管代谢疾病等多个领域，显示了其在多个疾病治疗领域的全面布局。

The data used to train the AI – including vaccination records, GP visits, hospital admissions, and A&E attendances – is being ...

Apple (AAPL, Financials) is appealing a federal judge's finding of contempt in its ongoing antitrust battle with Epic Games ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...